ALK F1174V

CI-VAR-00001070Explore in graph →NP_004295.2:p.Phe1174ValNM_004304.4:c.3520T>GClinVar 65670 CIViC 1505 rs281864719

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
ALK F1174V	Crizotinib	Predictive	C	Supports Resistance	—	submitted	EID4473 In a phase 2 study (NCT0093245), a stage IV non-small cell lung cancer patient with acquired crizotinib resistance harbored an EML4-ALK gene rearrangement (a known sensitizing alteration to crizotinib… (full text at CIViC) PMID 24736079 · Ignatius Ou et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
65670	Pathogenic	no assertion criteria provided	0	Neuroblastoma, susceptibility to, 3	germline/somatic	2	Oct 07, 2015	clinvar